Another trial (22) retrospectively studied KRAS mutant non-small cell lung cancer patients treated with ICIs, suggesting mPFS (4.6 vs. 3.3 months) in KRAS mutant and non-KRAS mutant patients, but the results were not significant. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.